{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04359199",
            "orgStudyIdInfo": {
                "id": "190048"
            },
            "organization": {
                "fullName": "University of California, San Diego",
                "class": "OTHER"
            },
            "briefTitle": "QUantitative Assessment of Swallowing After Radiation (QUASAR)",
            "officialTitle": "QUantitative Assessment of Swallowing After Radiation (QUASAR): A Longitudinal Comparison of Swallowing Function by Systemic Therapy in Head and Neck Cancer Patients",
            "acronym": "QUASAR",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "quantitative-assessment-of-swallowing-after-radiation-quasar"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2020-09-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2023-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-04-20",
            "studyFirstSubmitQcDate": "2020-04-20",
            "studyFirstPostDateStruct": {
                "date": "2020-04-24",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-02-09",
            "lastUpdatePostDateStruct": {
                "date": "2023-02-10",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Loren Mell, MD",
                "investigatorTitle": "Director, Division of Clinical and Translational Research/ Department of Radiation Medicine and Applied Sciences",
                "investigatorAffiliation": "University of California, San Diego"
            },
            "leadSponsor": {
                "name": "Loren Mell, MD",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "To use novel methods for quantitative analysis of VFSS (videofluoroscopic swallow study, also known as modified barium swallow) to study and compare dysphagia in patients treated for head and neck carcinoma with concurrent radiation therapy and chemotherapy (cisplatin) or targeted therapy (cetuximab) vs. immunotherapy (pembrolizumab, nivolumab, or durvalumab).\n\nOur hypothesis is that pharyngeal constriction will be greater (lower ratio) with concurrent immunotherapy compared to chemotherapy, as measured by the pharyngeal constriction ratio (PCR).",
            "detailedDescription": "The QUASAR study will use a prospective, observational, cross sectional design (See Schema). HNC patients treated with definitive RT and immunotherapy or chemotherapy (cetuximab or cisplatin) will undergo VFSS at 4-6 and 12-24 months post-treatment. Patients enrolled prior to 6 months after finishing therapy will undergo a swallow study during the 4-6 month period AND the 12-24 month period. Patients enrolled after 6 months after finishing therapy will undergo a single swallow study in the 12-24 month period. The primary endpoint of PCR at 12-24 months will be compared between patients treated with immunotherapy versus chemotherapy.\n\nAll patients with HNC treated with definitive RT and systemic therapy at our institution will be eligible. In particular, we will recruit patients for this study from participants in two ongoing trials investigating the use of concurrent immunotherapy. The KEYCHAIN trial (ClinicalTrials.gov Identifier: NCT03383094) randomizes patients with locally advanced p16+ HNC undergoing definitive RT to concurrent q3 week cisplatin versus concurrent and adjuvant pembrolizumab. NRG-HN004 (ClinicalTrials.gov Identifier: NCT03258554) is a cooperative group trial that compares HNC patients that are not eligible for cisplatin undergoing definitive radiation therapy to concurrent cetuximab versus durvalumab."
        },
        "conditionsModule": {
            "conditions": [
                "Head and Neck Cancer",
                "Dysphagia",
                "Oropharyngeal Dysphagia",
                "Oropharynx Cancer",
                "Oropharynx Squamous Cell Carcinoma"
            ],
            "keywords": [
                "head and neck cancer",
                "oropharyngeal dysphagia",
                "radiation therapy",
                "immunotherapy",
                "videofluoroscopic swallow study",
                "modified barium swallow study",
                "oropharynx cancer",
                "oropharynx squamous cell carcinoma"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "OTHER",
                "timePerspective": "CROSS_SECTIONAL"
            },
            "enrollmentInfo": {
                "count": 42,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Radiotherapy with chemotherapy",
                    "description": "Patients treated with definitive RT and chemotherapy (cisplatin) or targeted therapy (cetuximab)",
                    "interventionNames": [
                        "Radiation: Radiation Therapy",
                        "Drug: Cetuximab",
                        "Drug: Chemotherapy"
                    ]
                },
                {
                    "label": "Radiotherapy with immunotherapy",
                    "description": "Patients treated with definitive RT and immunotherapy (pembrolizumab, nivolumab, or durvalumab)",
                    "interventionNames": [
                        "Radiation: Radiation Therapy",
                        "Drug: Immunotherapy"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "RADIATION",
                    "name": "Radiation Therapy",
                    "description": "Routine radiation dosing (approximately 70 Gy in 35 fractions over 6.5 weeks) to the head and neck for the treatment of head and neck cancer",
                    "armGroupLabels": [
                        "Radiotherapy with chemotherapy",
                        "Radiotherapy with immunotherapy"
                    ],
                    "otherNames": [
                        "radiotherapy",
                        "RT"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cetuximab",
                    "description": "Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of head and neck cancer",
                    "armGroupLabels": [
                        "Radiotherapy with chemotherapy"
                    ],
                    "otherNames": [
                        "Erbitux"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Chemotherapy",
                    "description": "Cisplatin is a chemotherapy medication used to treat a number of cancers, including head and neck cancer",
                    "armGroupLabels": [
                        "Radiotherapy with chemotherapy"
                    ],
                    "otherNames": [
                        "Cisplatin"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Immunotherapy",
                    "description": "Keytruda or Pembrolizumab is a highly selective humanized monoclonal IgG4 antibody directed against the PD-1 receptor on the cell surface.\n\nOpdivo or Nivolumab is a targeted therapy. It is a human programmed death receptor-1 (PD-1) blocking antibody.\n\nImfinzi or Durvalumab is an anti-cancer (\"antineoplastic\") drug. This medication is classified as an Anti-PD-L1 monoclonal antibody.",
                    "armGroupLabels": [
                        "Radiotherapy with immunotherapy"
                    ],
                    "otherNames": [
                        "pembrolizumab",
                        "Keytruda",
                        "nivolumab",
                        "Opdivo",
                        "durvalumab",
                        "Imfinzi"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Swallowing function 12-24 months after concurrent radiation and systemic therapy for HNC, as measured by the PCR",
                    "description": "will use a two-sample t-test at 0.05 level to compare Pharyngeal Constriction Ratio (PCR) between groups",
                    "timeFrame": "12-24 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Quantitative swallowing function at 4-6 months and 12-24 months by PCR, TPT, PRR and PPWT",
                    "description": "To compare swallowing function between systemic therapies with additional quantitative metrics of swallowing dysfunction from the VFSS including TPT, PRR and PPWT.\n\nThe presence of aspiration or strictures on VFSS will be compared as binary variables between groups using Pearson's Chi squared test.",
                    "timeFrame": "4-6 months and 12-24 months"
                },
                {
                    "measure": "Correlation between quantitative swallowing function and patient reported symptoms using the EAT-10 tool",
                    "description": "To compare patient reported assessments of swallowing function with the EAT-10 tool between systemic therapies.\n\nTo test if there is correlation between the quantitative VFSS metrics and patient reported outcomes on the EAT-10 index, we will calculate Pearson's correlation coefficient and plot the results on a correlation matrix. The Holm step down procedure will be used to adjust for multiple testing to control the family-wise error rate at 0.05 level.",
                    "timeFrame": "12-24 months"
                },
                {
                    "measure": "Correlation between radiation dose and location of swallowing function and quantitative swallowing function",
                    "description": "The purpose of this aim is to evaluate the effect of radiation dose on swallowing structures, applying a previously developed space-preserving NTCP approach based on principal component analysis (PCA).\n\nUsing this approach, dose distributions to the global swallowing apparatus (i.e. pharynx, larynx and esophagus) will be standardized for patients from both arms of Aim 1, using deformable registration to standardize organs and 3-D dose distributions to a common template. Dose distributions will be converted into a dose array and PCA will be applied to the dose array, as previously described. We will then use PC linear regression to identify eigenvectors significantly associated with long term dysphagia (as measured by PCR).",
                    "timeFrame": "24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Biopsy-proven, un-resected invasive carcinoma of the head and neck.\n* Treated with definitive RT and concurrent systemic therapy or treated within the past 4-24 months\n* Concurrent systemic therapy with Cisplatin, Cetuximab or immunotherapy.\n* Age \u2265 18\n* Able to understand and willing to sign a written informed consent.\n\nExclusion Criteria:\n\n* Prior radiotherapy that would result in overlap of planned radiation therapy fields.\n* Prior systemic chemotherapy, unless as part of the coordinated plan of care for the treatment of the carcinoma (e.g., induction/neoadjuvant chemotherapy is allowed)\n* Planned adjuvant (i.e., following definitive chemoradiotherapy) chemotherapy or surgery",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Patients with head and neck carcinoma treated with definitive radiation therapy and systemic therapy (chemotherapy or immunotherapy) in the University of California San Diego Healthcare System will be eligible.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Khusbu Singh, MBBS, CCRP",
                    "role": "CONTACT",
                    "phone": "858-245-2604",
                    "email": "ksingh@health.ucsd.edu"
                },
                {
                    "name": "Gerald Henderson",
                    "role": "CONTACT",
                    "phone": "858-534-4811",
                    "email": "gehenderson@health.ucsd.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Loren K Mell, MD",
                    "affiliation": "University of California, San Diego",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "UC San Diego Moores Cancer Center",
                    "status": "RECRUITING",
                    "city": "La Jolla",
                    "state": "California",
                    "zip": "92093",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Khushbu Singh, MBBS, CCRP",
                            "role": "CONTACT",
                            "phone": "858-246-2604"
                        },
                        {
                            "name": "Loren Mell, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.84727,
                        "lon": -117.2742
                    }
                },
                {
                    "facility": "UCSD Moores Cancer Center",
                    "status": "RECRUITING",
                    "city": "La Jolla",
                    "state": "California",
                    "zip": "92093",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Gerald Henderson, BA",
                            "role": "CONTACT",
                            "phone": "858-822-5223",
                            "email": "gehenderson@ucsd.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.84727,
                        "lon": -117.2742
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "26371282",
                    "type": "BACKGROUND",
                    "citation": "Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015 Dec;26(12):2375-91. doi: 10.1093/annonc/mdv383. Epub 2015 Sep 14. Erratum In: Ann Oncol. 2016 Jul;27(7):1362. doi: 10.1093/annonc/mdw141."
                },
                {
                    "pmid": "17081915",
                    "type": "BACKGROUND",
                    "citation": "Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006 Nov;7(11):903-9. doi: 10.1016/S1470-2045(06)70910-X."
                },
                {
                    "type": "BACKGROUND",
                    "citation": "Leonard R, Kendall K. Dysphagia Assessment and Treatment Planning: A Team Approach. Fourth. Plural Publishing; 2018"
                },
                {
                    "pmid": "12497197",
                    "type": "BACKGROUND",
                    "citation": "Stoeckli SJ, Huisman TA, Seifert B, Martin-Harris BJ. Interrater reliability of videofluoroscopic swallow evaluation. Dysphagia. 2003 Winter;18(1):53-7. doi: 10.1007/s00455-002-0085-0."
                },
                {
                    "pmid": "16890070",
                    "type": "BACKGROUND",
                    "citation": "Yip H, Leonard R, Belafsky PC. Can a fluoroscopic estimation of pharyngeal constriction predict aspiration? Otolaryngol Head Neck Surg. 2006 Aug;135(2):215-7. doi: 10.1016/j.otohns.2006.03.016."
                },
                {
                    "pmid": "19856026",
                    "type": "BACKGROUND",
                    "citation": "Leonard R, Rees CJ, Belafsky P, Allen J. Fluoroscopic surrogate for pharyngeal strength: the pharyngeal constriction ratio (PCR). Dysphagia. 2011 Mar;26(1):13-7. doi: 10.1007/s00455-009-9258-4. Epub 2009 Oct 24."
                },
                {
                    "pmid": "24924114",
                    "type": "BACKGROUND",
                    "citation": "Servagi-Vernat S, Ali D, Roubieu C, Durdux C, Laccourreye O, Giraud P. Dysphagia after radiotherapy: state of the art and prevention. Eur Ann Otorhinolaryngol Head Neck Dis. 2015 Feb;132(1):25-9. doi: 10.1016/j.anorl.2013.09.006. Epub 2014 Jun 9."
                },
                {
                    "pmid": "17673322",
                    "type": "BACKGROUND",
                    "citation": "Jensen K, Lambertsen K, Grau C. Late swallowing dysfunction and dysphagia after radiotherapy for pharynx cancer: frequency, intensity and correlation with dose and volume parameters. Radiother Oncol. 2007 Oct;85(1):74-82. doi: 10.1016/j.radonc.2007.06.004. Epub 2007 Jul 27."
                },
                {
                    "pmid": "23429941",
                    "type": "BACKGROUND",
                    "citation": "Duprez F, Madani I, De Potter B, Boterberg T, De Neve W. Systematic review of dose--volume correlates for structures related to late swallowing disturbances after radiotherapy for head and neck cancer. Dysphagia. 2013 Sep;28(3):337-49. doi: 10.1007/s00455-013-9452-2. Epub 2013 Feb 22."
                },
                {
                    "pmid": "20472344",
                    "type": "BACKGROUND",
                    "citation": "Liang Y, Messer K, Rose BS, Lewis JH, Jiang SB, Yashar CM, Mundt AJ, Mell LK. Impact of bone marrow radiation dose on acute hematologic toxicity in cervical cancer: principal component analysis on high dimensional data. Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):912-9. doi: 10.1016/j.ijrobp.2009.11.062. Epub 2010 May 14."
                },
                {
                    "pmid": "30406032",
                    "type": "RESULT",
                    "citation": "Green G, Kim E, Carmona R, Shen H, Murphy JD, Mell LK. Incidence of Long-Term Esophageal Dilation With Various Treatment Approaches in the Older Head and Neck Cancer Population. Front Oncol. 2018 Oct 23;8:466. doi: 10.3389/fonc.2018.00466. eCollection 2018."
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002294",
                    "term": "Carcinoma, Squamous Cell"
                },
                {
                    "id": "D000006258",
                    "term": "Head and Neck Neoplasms"
                },
                {
                    "id": "D000009959",
                    "term": "Oropharyngeal Neoplasms"
                },
                {
                    "id": "D000003680",
                    "term": "Deglutition Disorders"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000018307",
                    "term": "Neoplasms, Squamous Cell"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000004935",
                    "term": "Esophageal Diseases"
                },
                {
                    "id": "D000005767",
                    "term": "Gastrointestinal Diseases"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000010608",
                    "term": "Pharyngeal Diseases"
                },
                {
                    "id": "D000010038",
                    "term": "Otorhinolaryngologic Diseases"
                },
                {
                    "id": "D000010610",
                    "term": "Pharyngeal Neoplasms"
                },
                {
                    "id": "D000010039",
                    "term": "Otorhinolaryngologic Neoplasms"
                },
                {
                    "id": "D000009057",
                    "term": "Stomatognathic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M6882",
                    "name": "Deglutition Disorders",
                    "asFound": "Dysphagia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5550",
                    "name": "Carcinoma, Squamous Cell",
                    "asFound": "Squamous Cell Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9348",
                    "name": "Head and Neck Neoplasms",
                    "asFound": "Head and Neck Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12885",
                    "name": "Oropharyngeal Neoplasms",
                    "asFound": "Oropharynx Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M20451",
                    "name": "Neoplasms, Squamous Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M8085",
                    "name": "Esophageal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13515",
                    "name": "Pharyngeal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12961",
                    "name": "Otorhinolaryngologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13517",
                    "name": "Pharyngeal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M12962",
                    "name": "Otorhinolaryngologic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M12017",
                    "name": "Stomatognathic Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "BC09",
                    "name": "Ear, Nose, and Throat Diseases"
                },
                {
                    "abbrev": "BC07",
                    "name": "Mouth and Tooth Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002945",
                    "term": "Cisplatin"
                },
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                },
                {
                    "id": "D000077594",
                    "term": "Nivolumab"
                },
                {
                    "id": "D000068818",
                    "term": "Cetuximab"
                },
                {
                    "id": "C000613593",
                    "term": "Durvalumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M272500",
                    "name": "Durvalumab",
                    "asFound": "Pancreatic",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1854",
                    "name": "Nivolumab",
                    "asFound": "Technique",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M4230",
                    "name": "Antibodies, Monoclonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M6182",
                    "name": "Cisplatin",
                    "asFound": "Children",
                    "relevance": "HIGH"
                },
                {
                    "id": "M315",
                    "name": "Cetuximab",
                    "asFound": "Physician",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11900",
                    "name": "Mitogens",
                    "relevance": "LOW"
                },
                {
                    "id": "M21134",
                    "name": "Antibodies, Blocking",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}